Switching from a regimen containing abacavir/lamivudine or emtricitabine/tenofovir disoproxil fumarate to emtricitabine/tenofovir alafenamide fumarate does not affect central nervous system HIV-1 infection

Autor:	Magnus Gisslén, Kaj Blennow, Dietmar Fuchs, Aylin Yilmaz, Staffan Nilsson, Henrik Zetterberg, Åsa Mellgren
Rok vydání:	2019
Předmět:	Adult Central Nervous System Male 0301 basic medicine Microbiology (medical) Anti-HIV Agents 030106 microbiology Central nervous system Human immunodeficiency virus (HIV) HIV Infections Pilot Projects medicine.disease_cause 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Emtricitabine/Tenofovir Disoproxil Fumarate medicine Emtricitabine Humans Prospective Studies 030212 general & internal medicine Tenofovir Aged Emtricitabine tenofovir alafenamide Alanine General Immunology and Microbiology Drug Substitution business.industry Adenine Neopterin General Medicine Abacavir/Lamivudine Middle Aged Viral Load Virology Dideoxynucleosides Drug Combinations Regimen Infectious Diseases medicine.anatomical_structure chemistry Lamivudine Female business medicine.drug Immune activation
Zdroj:	Infectious Diseases. 51:838-846
ISSN:	2374-4243 2374-4235
Popis:	Background: Despite suppressive antiretroviral therapy (ART), many HIV-infected individuals have low-level persistent immune activation in the central nervous system (CNS). There have been ...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88e857684e9beedd1588699ed355063f https://doi.org/10.1080/23744235.2019.1670352 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.